Taisho Pharmaceutical Holdings Co., Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Taisho Pharmaceutical Holdings Co., Ltd. generated cash of $40,972,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$10,877,000,000 last year. Net change in cash is therefore $4,561,000,000.
Cash Flow
| 2014 | 60.23B | -21.99B | -9.43B |
|---|---|---|---|
| 2015 | 33.71B | -18.16B | -9.44B |
| 2016 | 43.05B | -11.66B | -19.52B |
| 2017 | 40.06B | -1.36B | -8.40B |
| 2018 | 39.85B | -19.90B | -9.86B |
| 2019 | 19.22B | 66.04B | -15.46B |
| 2020 | 41.99B | -107.08B | -11.69B |
| 2021 | 42.02B | -1.95B | -11.34B |
| 2022 | 28.50B | -7.06B | -10.05B |
| 2023 | 40.97B | -27.13B | -10.87B |
TAIPY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 227.51B | 215.34B | 186.94B | 263.54B | 194.36B | 184.22B | 154.26B | 143.03B | 136.13B | 106.11B |
Operating activities | ||||||||||
Net income | 29.49B | 21.39B | 22.97B | 30.31B | 64.48B | 48.07B | 41.95B | 35.80B | 40.16B | 51.31B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 24.64B | 23.07B | 22.04B | 16.69B | 11.29B | 11.38B | 11.67B | 12.47B | 12.93B | 12.38B |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 2.81B | -2.86B | 13.66B | 11.84B | 3.68B | 0 | 0 | 0 | 0 | 0 |
Inventories | -6.93B | 2.53B | -2.90B | 1.60B | -2.78B | 1.16B | -1.02B | 465M | -5M | -1.13B |
Accounts payable | 1.25B | 384M | -3.30B | -4.92B | -1.05B | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 40.97B | 28.50B | 42.02B | 41.99B | 19.22B | 39.85B | 40.06B | 43.05B | 33.71B | 60.23B |
Investing activities | ||||||||||
Purchases Of Investments | -3.41B | -1.26B | -2.06B | -1.85B | -18.86B | -12.47B | -20.82B | -11.14B | -24.5B | -23.01B |
Investments In Property Plant And Equipment | -50.37B | -14.38B | -14.37B | -9.12B | -4.91B | -5.01B | -8.83B | -8.21B | -5.76B | -14.86B |
Acquisitions Net | 1.51B | -4.31B | -4.08B | -160.49B | 70.57B | -434M | -12.26B | -1.25B | 1M | -2.66B |
Cash generated by investing activities | -27.13B | -7.06B | -1.95B | -107.08B | 66.04B | -19.90B | -1.36B | -11.66B | -18.16B | -21.99B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 2.52B | -525M | 0 | -633M | 0 | -219M | 0 | -177M |
Payments for dividends | -8.20B | -7.41B | -8.78B | -9.58B | 0 | -8.77B | -7.97B | -8.90B | -8.9B | -8.89B |
Repurchases of common stock | -34M | -43M | -41M | -48M | -341M | -96M | -100M | -10.09B | -97M | -110M |
Repayments of term debt | -622M | 95M | -5.03B | -1.53B | 24M | -365M | 58M | -305M | -55M | -255M |
Cash used in financing activities | -10.87B | -10.05B | -11.34B | -11.69B | -15.46B | -9.86B | -8.40B | -19.52B | -9.44B | -9.43B |
Net Change In Cash | 4.56B | 12.16B | 28.40B | -76.60B | 69.18B | 10.14B | 29.95B | 11.22B | 6.90B | 30.01B |
Cash at end of period | 232.07B | 227.51B | 215.34B | 186.94B | 263.54B | 194.36B | 184.22B | 154.26B | 143.03B | 136.13B |